(NASDAQ: NUVA) NUVASIVE's forecast annual revenue growth rate of 6.58% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.93%.
NUVASIVE's revenue in 2022 is $1,158,501,000.On average, 5 Wall Street analysts forecast NUVA's revenue for 2022 to be $63,680,734,934, with the lowest NUVA revenue forecast at $63,492,658,652, and the highest NUVA revenue forecast at $63,886,609,249. On average, 5 Wall Street analysts forecast NUVA's revenue for 2023 to be $68,351,001,048, with the lowest NUVA revenue forecast at $67,995,248,567, and the highest NUVA revenue forecast at $69,089,671,428.
In 2024, NUVA is forecast to generate $72,971,932,266 in revenue, with the lowest revenue forecast at $72,826,217,382 and the highest revenue forecast at $73,117,647,150.